FORM
6-K
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES
EXCHANGE ACT OF 1934
For
the Month of May, 2024
Commission
File Number 0-51504
GENETIC
TECHNOLOGIES LIMITED
(Exact
Name as Specified in its Charter)
N/A
(Translation
of Registrant’s Name)
60-66
Hanover Street
Fitzroy
Victoria
3065 Australia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Report on Form 6-K (including exhibits thereto) is hereby incorporated by reference into the registrant’s Registration Statement
on Form F-3 (File Nos. 333-276168), to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
May 28, 2024
GENETIC
TECHNOLOGIES LIMITED |
|
|
|
By: |
/s/
Kathryn Andrews |
|
Name: |
Kathryn
Andrews |
|
Title: |
Company
Secretary |
|
Exhibit
99.1
ASX
Market Announcement |
![](https://www.sec.gov/Archives/edgar/data/1166272/000149315224021716/ex99-1_001.jpg) |
GTG
Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
Melbourne,
Australia, May 29, 2024: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global
leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive
Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all
women above the age of 30, assesses a woman’s risk of cancer due to hereditary, including those with common gene mutations, and
sporadic disease.
Launched
at the inaugural “Know Your Risk” event in California, USA, the event provided invaluable insights of the role of genomics
in women’s health. Co-hosted by Dr Kristi Funk, known for her surgical treatment of celebrity Angelina Jolie, alongside CEO &
Founder of Humanise Health, Krystal Barter, the event also featured panellists such as US based OB-GYN Dr. Carolynn Young, Andrea Hans,
Allyn Rose Oertel, and Matthew Zachary.
This
new geneType Comprehensive Risk Assessment test represents a significant leap in preventative healthcare, whereby clinicians will have
a complete understanding of their patient’s risk profile of developing one of the deadly cancers. The addition of the germline
component to GTG’s platform provided the ability to screen 100% of women at risk. Retrospective data shows 5% to 10% of breast
and ovarian cancers are caused by gene mutations and the remainder are due to sporadic condition.
This
represents a massive market opportunity for geneType, with 1 in 8 chances of a woman in the US developing breast cancer equating to about
310,000 diagnosed cases annually. Although less prevalent, ovarian cancer accounts for 19,600 cases diagnosed yearly in the US and claims
12,700 deaths annually. Ovarian cancer is more deadly and is among the leading cause of cancer deaths in women1. Dr Kirsti
Funk noted that “Understanding your cancer risk based on critical diet and lifestyle and genetic factors allows me to create a
more directed, effective risk-reducing strategy.2”
This
advancement in personalised preventative healthcare, was welcomed by the company’s strategic partners in employer groups, functional
medicine clinics and existing physician networks. The OB-GYNs are overwhelmingly excited about this launch and expressed their satisfactions
on the abilities of our new comprehensive test for early diagnosis and ultimately saving lives.
GTG’s
CEO, Simon Morriss, said “We are incredibly proud to have been part of this ‘Know Your Risk’ event which underscored
the importance of genetic testing and risk assessment in transforming women’s health, inspiring attendees to advocate for their
health and well-being proactively. We are also very fortunate and to have the opportunity to launch this unique risk assessment test
in the presence of such a wonderful group of people”.
Peter
Rubinstein, GTG’s Chairman commented, “We are also excited to announce that in preparation for significant demand for this
revolutionary test we have fully onboarded a high throughput automated laboratory in the United States with capacity to scale up to run
100,000 tests per month should future demand require. Every woman deserves the right to know her risk”.
For
more information, please visit www.genetype.com
-
END -
1
https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html
2
https://www.instagram.com/p/C7XX-sKygdG/?utm_source=ig_web_copy_link
Authorised
for release by the Board of Directors.
Enquiries
Simon
Morriss
Chief
Executive Officer
E:
investors@genetype.com
About
Genetic Technologies Limited
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests
in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment
tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform
that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and
individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues
to develop risk assessment products. For more information, please visit www.genetype.com
Forward
Looking Statements
This
announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other
things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made
or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”
or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made
by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated
or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause
the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the
ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities
values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any
obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by law.
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Aug 2023 to Aug 2024